Work

656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.052

Authors: D.F. McDermott, T.K. Choueiri, T.M. Bauer, E. Arrowsmith, A. Roy, R. Perini, D. Vickery, S.S. Tykodi

Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Tennessee Oncology, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204595641

FWCI: 1.131

Cites:

Cited by: 8

Related to: 10